Cagrilintide is a long-acting analogue of amylin.

It is being tested to treat obesity and type 2 diabetes by itself and in combination with semaglutide as cagrilintide/semaglutide.

[1][2][3][4][5][6] A systematic review and metanalysis of cagrisema, published in 2024, found that cagrisema may provide weight loss benefits.

This pharmacology-related article is a stub.

You can help Wikipedia by expanding it.